{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:01:52Z","timestamp":1790049712573,"version":"4.0.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ejpn.2023.01.011","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T02:19:47Z","timestamp":1674785987000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Ocrelizumab in pediatric multiple sclerosis"],"prefix":"10.1016","volume":"43","author":[{"given":"Ceren","family":"Bibino\u011flu Amirov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sema","family":"Salt\u0131k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3443-8524","authenticated-orcid":false,"given":"Cengiz","family":"Yal\u00e7\u0131nkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melih","family":"T\u00fct\u00fcnc\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabahattin","family":"Saip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8340-6641","authenticated-orcid":false,"given":"Aksel","family":"Siva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U\u011fur","family":"Uyguno\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejpn.2023.01.011_bib1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.59.7.1006","article-title":"Early onset multiple sclerosis: a longitudinal study","volume":"59","author":"Boiko","year":"2002","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.ejpn.2023.01.011_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awaa199","article-title":"Improved relapse recovery in paediatric compared to adult multiple sclerosis","volume":"143","author":"Chitnis","year":"2020","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.ejpn.2023.01.011_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/glia.23624","article-title":"Aging restricts the ability of mesenchymal stem cells to promote the generation of oligodendrocytes during remyelination","volume":"67","author":"Rivera","year":"2019","journal-title":"Glia"},{"issue":"2","key":"10.1016\/j.ejpn.2023.01.011_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2012-303996","article-title":"Long-term outcome of paediatric-onset multiple sclerosis: a population-based study","volume":"84","author":"Harding","year":"2013","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"8","key":"10.1016\/j.ejpn.2023.01.011_bib5","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000001856","article-title":"Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis","volume":"85","author":"Novotna","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2023.01.011_bib6","series-title":"Guideline on Clinical Investigation of Medicinal Products for the Treatment of Multiple Sclerosis","year":"2015"},{"issue":"11","key":"10.1016\/j.ejpn.2023.01.011_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/0883073812456084","article-title":"Pathogenesis of pediatric multiple sclerosis","volume":"27","author":"Vargas-Lowy","year":"2012","journal-title":"J.\u00a0Child Neurol."},{"key":"10.1016\/j.ejpn.2023.01.011_bib9","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.ejpn.2023.01.011_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2020-000108","article-title":"Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study","volume":"3","author":"Smoot","year":"2021","journal-title":"BMJ Neurol Open"},{"key":"10.1016\/j.ejpn.2023.01.011_bib12","series-title":"Medication Guide Ocrevus","year":"2009"},{"key":"10.1016\/j.ejpn.2023.01.011_bib13","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","author":"Hauser","year":"2017","journal-title":"N Engl J Med. Published online"},{"issue":"1","key":"10.1016\/j.ejpn.2023.01.011_bib14","doi-asserted-by":"crossref","DOI":"10.1177\/1352458517732843","article-title":"Therapy of highly active pediatric multiple sclerosis","volume":"25","author":"Huppke","year":"2019","journal-title":"Mult. Scler. J"},{"issue":"9","key":"10.1016\/j.ejpn.2023.01.011_bib15","article-title":"Pediatric multiple sclerosis Clinical features and outcome","volume":"87","author":"Waldman","year":"2016","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.ejpn.2023.01.011_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awp278","article-title":"Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis","volume":"132","author":"Yeh","year":"2009","journal-title":"Brain"},{"issue":"25","key":"10.1016\/j.ejpn.2023.01.011_bib17","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa067597","article-title":"Natural history of multiple sclerosis with childhood onset","volume":"356","author":"Renoux","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ejpn.2023.01.011_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2018.20588","article-title":"Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis","volume":"321","author":"Brown","year":"2019","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.ejpn.2023.01.011_bib19","doi-asserted-by":"crossref","DOI":"10.1007\/s11940-019-0592-z","article-title":"Newer treatment approaches in pediatric-onset multiple sclerosis","author":"Macaron","year":"2019","journal-title":"Curr. Treat. Options Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2023.01.011_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/ana.25737","article-title":"Real-world effectiveness of initial disease-modifying therapies in pediatric multiple sclerosis","volume":"88","author":"Krysko","year":"2020","journal-title":"Ann. Neurol."},{"issue":"9","key":"10.1016\/j.ejpn.2023.01.011_bib21","article-title":"Pediatric multiple sclerosis: escalation and emerging treatments","volume":"87","author":"Chitnis","year":"2016","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.ejpn.2023.01.011_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/1352458520932798","article-title":"Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: practical considerations","volume":"27","author":"Ghezzi","year":"2021","journal-title":"Mult. Scler. J"},{"key":"10.1016\/j.ejpn.2023.01.011_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/1352458511430704","article-title":"Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis","author":"Chitnis","year":"2012","journal-title":"Mult Scler J."},{"issue":"1","key":"10.1016\/j.ejpn.2023.01.011_bib24","article-title":"Towards the implementation of \u2018no evidence of disease activity\u2019\u2019 in multiple sclerosis treatment: the multiple sclerosis decision model","volume":"8","author":"Stangel","year":"2015","journal-title":"\u2019 Ther Adv Neurol Disord."},{"issue":"2","key":"10.1016\/j.ejpn.2023.01.011_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2014.3537","article-title":"Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort","volume":"72","author":"Rotstein","year":"2015","journal-title":"JAMA Neurol."}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379823000119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379823000119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:39:52Z","timestamp":1761071992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379823000119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":23,"alternative-id":["S1090379823000119"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2023.01.011","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocrelizumab in pediatric multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2023.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}